MUC16 and prostate carcinoma: Typical examples include targeting alterations in N-glycan antennas, fucosylation and sialylation in prostate specific antigen (PSA) to improve the PSA test limited sensitivity for non-invasive detection of prostate cancer 165-167 or exploring the glycosylation state of MUC16 (CA125) for ovarian cancer 168 (Figure 6).